BIO-Europe Spring 2019: Virion CEO Outlines Plans For The First Broad-Spectrum Respiratory Antiviral
Today, the vast majority of respiratory viruses are not addressable with either vaccines or treatments. Virion Biotherapeutics is aiming to change that, using scientific knowledge developed at the University of Warwick. CEO Vanessa King spoke to Scrip at BIO-Europe Spring 2019.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.